Disc Medicine (IRON) reported a 2024 loss Thursday of $3.96 per share, wider than a loss of $3.42 a year earlier.
Analysts polled by FactSet expected a loss of $4.13.
As expected, no revenue was reported.
As of Dec. 31, the company had $489.9 million in cash, cash equivalents and marketable securities. Combined with $243.3 million from an underwritten public offering, the company said it expects this will fund its operations into 2028.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。